2,562 results on '"Perales, Miguel-Angel"'
Search Results
2. Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimus
3. Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
4. Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease
5. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
6. Post-transplantation cyclophosphamide is associated with increased bacterial infections
7. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
8. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.
9. Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis
10. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
11. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant
12. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
13. ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy
14. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
15. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
16. Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
17. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management
18. Recruitment and Retention of Hematopoietic Cell Transplantation and Cellular Therapy Physicians: A Report from the ASTCT Talent Acquisition Task Force
19. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
20. Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome
21. EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation
22. The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant—a CIBMTR study
23. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
24. Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity
25. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
26. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma
27. CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas
28. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
29. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
30. Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation
31. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
32. National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide
33. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant
34. Circulating microbial cell–free DNA is increased during neutropenia after hematopoietic stem cell transplantation
35. Emergence of human CMV-induced NKG2C+ NK cells is associated with CD8+ T-cell recovery after allogeneic HCT
36. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy
37. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
38. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation
39. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
40. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma
41. Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia
42. The TaxUMAP atlas: Efficient display of large clinical microbiome data reveals ecological competition in protection against bacteremia
43. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
44. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
45. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
46. High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients
47. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study
48. Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation
49. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies
50. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.